Pulse biosciences, inc. (PLSE)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net loss

-11,872

-13,788

-11,746

-11,359

-10,078

-8,953

-10,761

-9,163

-8,668

-8,703

-7,486

-6,180

-3,198

-2,809

-2,767

-2,258

-1,684

-1,017

-751

-599

-444

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

104

104

90

138

162

171

165

156

153

140

147

25

24

24

24

24

22

20

11

10

10

Amortization of intangible assets

166

166

167

166

167

166

166

167

166

166

166

167

166

166

167

166

166

167

167

166

166

Stock-based compensation

2,626

3,548

2,679

2,699

2,361

2,350

3,393

3,175

3,420

4,523

3,350

2,790

263

243

238

196

193

135

106

107

54

Net premium amortization and discount on available-for-sale securities

4

63

167

195

96

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net premium amortization and discount on available-for-sale securities

-

-

-

-

-

-

-

-

10

-

-

-

-

-

-

-

-

-

-

-

-

Net discount amortization on investments

-

-

-

-

-

-

-

-

-

-

10

9

5

-

-

-

-

-

-

-

-

Change in deferred income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-518

-483

-357

-299

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-460

-432

-471

1,358

-229

-316

-66

793

-44

-100

-205

464

-15

165

-256

503

3

-7

-6

6

19

Right-of-use assets

-71

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term assets

68

-2,341

8

2,619

107

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

146

-

-

-

-

Accounts payable

-749

102

239

377

-72

-9

-221

558

162

-132

63

69

517

-181

113

37

34

-32

39

62

56

Accrued expenses

-425

208

351

184

98

-236

493

318

-188

38

140

358

-291

190

197

-97

-44

211

1

35

58

Lease liabilities

69

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current and non-current liabilities

-

-

-41

2,273

6

-101

-102

-97

-97

-

-

-

-

-

-

-

-

-

-

-

-

Deferred grant revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

-1

0

-39

Net cash used in operating activities

-9,622

-9,196

-7,965

-9,694

-7,330

-6,308

-6,850

-5,720

-5,018

-3,963

-3,417

-1,208

-2,499

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,982

-2,289

-1,462

-

-948

-582

-457

Cash flows from investing activities:
Purchases of property and equipment

171

-37

533

67

45

33

72

137

34

-

-

-

-

0

3

22

39

-

-

-

-

Purchases of investments

3,006

5,012

17,913

10,882

44,186

498

10,689

9,953

19,157

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of investments

-

-

-

-

-

-

-

-

-

-

-

-

7,610

-

-

-

-

-

-

-

-

Maturities of investments

13,500

11,500

25,000

23,500

8,500

6,750

16,750

12,000

6,315

7,114

3,785

6,449

5,800

-

-

-

-

-

-

-

-

Sales of investments

-

-

-

-

-

0

0

0

24,875

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used) in investing activities

10,323

6,525

6,554

12,551

-35,731

6,219

5,989

1,910

11,999

-25,262

3,842

232

-1,810

-

-

-

-

-

-

-

-

Net cash provided by (used) in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-13,604

-517

-39

-

-

-

-

Cash flows from financing activities:
Proceeds from issuance of common stock under employee stock purchase plan

-

-

-

-

-

-

-

-

188

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock under employee stock purchase plan

255

-

-

-

272

-

-

-

-

-

29,979

0

4,965

-

-

-

-

-

-

-

-

Proceeds from exercises of stock options

9

-

0

50

222

-

259

52

112

-

30

164

6

-

-

-

-

-

-

-

-

Net cash provided by financing activities

264

0

201

-613

494

44,861

398

-63

300

188

30,008

215

4,971

-

-

-

-

-

-

-

-

Net increase (decrease) in cash

965

-2,671

-1,210

2,244

-42,567

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

20,915

0

-

0

0

0

Net increase (decrease) in cash

-

-

-

-

-

-

-

-

7,281

-

30,433

-761

662

-2,539

-15,586

18,109

-1,501

-1,343

-987

-616

-457

Supplemental disclosure of noncash investing and financing activities:
Change in unrealized gains on available-for-sale securities

13

-

-14

20

3

-

-3

3

48

-

-

-

-

-

-

-

-

-

-

-

-